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Evaluation of the potential kidney donor is a complex activity that diﬀers substantially from other types of preoperative
assessments. The well being of the donor, who derives no medical beneﬁt from this surgery, must be assured in both the short
term and long term, and the potential adverse consequences to the recipient must be determined as well. The criteria that
must be met for a person to donate a kidney are rigorous and include medical, social, psychosocial, ethical, and legal issues.
Donor evaluation can be divided into assessments to protect the health and safety of the donor and assessments to protect
the health and safety of the recipient. This article provides an approach to evaluating a donor, focusing on the complex issues
that an evaluator is faced with. A careful assessment of risks and beneﬁts to both the donor and recipient can lead to favorable
outcomes.
1.Introduction
A living kidney donor can improve the quality of life and
oﬀer a survival advantage to the recipient. Since 1998, as
per Organ Procurement and Transplantation Network data,
there have been approximately 309,319 kidney transplanta-
tions and of these approximately 108,150 are from living
kidney donors [1]. The shortage of living kidney donors is
one of the central issues that prolongs transplantation. This
shortage could be due to the stringent criteria that must be
applied to protect the health of the donor not only in the
perioperative period but long term as well.
The evaluation of a donor presents unique issues that
are addressed in a far diﬀerent manner compared to patients
undergoing other types of surgeries where the risk/beneﬁt
assessment is of a completely diﬀerent nature. A balance
between doing no harm to the donor while doing good for
the recipient must be achieved. This risk/beneﬁt analysis is
not always straightforward and may not be readily apparent
to the nontransplant evaluator.
The standard preoperative clearance does not apply
entirely to the kidney donor. The issues created by many
donors can be complex and thought provoking and require
thorough and detailed evaluations. Not only is a compre-
hensive review of their medical health necessary, but also
a complete assessment of their social and psychosocial well
being must be performed as well. In addition, ethical and
legal issues must be taken into consideration. Aside from
the general cardiovascular risk assessment which is needed
for all donors as well as addressing immunological issues
including blood typing and crossmatching, this article will
focus on the multifaceted issues that arise as a donor is being
evaluated, paying particular attention to the most common
dilemmas and challenges that we face when evaluating them.
These issues can be divided into two general categories:
assessments to protect the health and safety of the donor
and donor assessments to protect the health and safety of
the recipient. Both can be further subdivided into medical,
renal, lifestyle, and psychosocial issues. There is allowance of
overlap amongst the subcategorized issues [Table 1].2 Journal of Transplantation
Table 1: Summary of pretransplant donor evaluation.
Donor screening components Rationale
Screening to Protect the Donor
Medical
General medical/Cardiac preop assessment Perioperative and long-term risks
Diabetes Mellitus Risk of chronic kidney disease, cardiovascular disease
Hypertension Risk of chronic kidney disease, cardiovascular disease
Age Risk of chronic kidney disease
Pregnancy Rick of complications during pregnancy
Renal
Glomerular ﬁltration rate Risk of chronic kidney disease
Proteinuria Risk of chronic kidney disease
Hematuria Risk of chronic kidney disease
Nephrolithiasis Risk of kidney disease (acute and chronic)
Lifestyle
Overweight and obesity Metabolic, cardiovascular risks
Smoking Cardiovascular and possible renal risks
Assessment for high risk behaviors Long-term medical risks
Psychosocial
Psychosocial and psychiatric issues Short term and long-term exacerbation
Informed consent Risks related to not understanding, coercion
Donor screening to protect the recipient
Medical
Infection Risk of transmission of infection to recipient
Malignancy Risk of transmission of malignancy to recipient
Renal Risk of donor derived kidney disease
Lifestyle
Assessment for high-risk behaviors Potential for transmission of an unidentiﬁed infectious agent
2. Assessments to Protectthe Health
andSafetyof the Donor
2.1. General Medical Issues
2.1.1. Diabetes Mellitus. While diabetic patients and predia-
betic patients regularly undergo surgery, the approach in the
potential kidney donor is entirely diﬀerent. One concern is
that the presence of a single kidney in a diabetic patient may
result in an accelerated decline in kidney function if diabetic
nephropathy develops.
Most centers initiate screening with Hemoglobin A1C
(A1C), and/or fasting blood glucose (FBG). If a person
has any risk factors for developing diabetes mellitus or any
abnormalities in these initial tests, further evaluation with a
two-hour oral glucose tolerance test (2h-OGTT) is done [2].
Afastingbloodglucoseisperformedafteratleasteighthours
of no caloric intake. A 2h-OGTT is done two hours after a
75g oral glucose load is ingested.
Per American Diabetes Association guidelines, diagno-
sis of diabetes mellitus requires an A1C ≥6.5%, fasting
glucose ≥126mg/dL (7.0mmol/L), 2h-OGTT ≥200mg/dL
(11.1mmol/L), or a person with classic symptoms of
hyperglycemia or a random plasma glucose ≥200mg/dL
(11.1mmol/L) [3]. Due to the long-term microvascular and
macrovascular morbidity associated with diabetes mellitus
and the potential to accelerate the course of diabetic
nephropathy, these donors should not be allowed to donate.
The next group of donors includes those who do not
meet the criteria for diabetes. This group, termed the “pre-
diabetes” group, is deﬁned as having an A1C of 5.7–6.4%,
fasting glucose of 100mg/dL [5.6mmol/L] to 125mg/dL
[6.9mmol/L], or a 2h-OGTT value of 140mg/dL [7.8mmol/
L] to 199mg/dL [11.0mmol/L] [3]. In addition to their
increased risk of developing diabetes by 5% to 10% per year
[4], being in this group is a risk factor for cardiovascular
disease. Furthermore, this group has high associations with
obesity, hyperlipidemia, metabolic syndrome, or hyperten-
sion. According to a 2007 survey of kidney transplant centers
across the United States, 49% of programs exclude donors
based on elevated fasting blood glucose, however diﬀerent
cutoﬀs were used to deﬁne this [5]. Donors in this group
should be counseled appropriately on weight loss, diet
modiﬁcations, and exercise and should be discouraged from
donating.
Donors with a history of obesity, gestational diabetes, or
a strong family history of diabetes mellitus should undergo
testing with fasting glucose, 2-hr OGTT [2], and A1C.Journal of Transplantation 3
Checking anti-islet cell antibodies in potential donors with a
family history of diabetes can be done but its long-term cost
eﬀectiveness is unknown.
2.1.2. Hypertension. Hypertension has a well-known associ-
ation with the development of kidney disease. This needs to
be carefully addressed in potential kidney donors as loss of
renal mass in a hypertensive patient may increase the risk of
parenchymal renal disease developing, or may accelerate the
decline of kidney function in those patients in whom other
types of kidney disease develop.
The Joint National Committee Seventh Report intro-
duced a classiﬁcation for hypertension which included the
term prehypertension. They deﬁned prehypertension as
blood pressure ranging from 120–139mmHg systolic and/or
80–89mmHg diastolic. The classiﬁcation in hypertensives
is divided into stage 1 hypertension (systolic blood pres-
sure (SBP) 140–159mmHg and/or diastolic blood pressure
(DBP) 90–99mmHg) and stage 2 hypertension (SBP greater
than or equal to 160mmHg and/or DBP greater than
or equal to 100mmHg). With this classiﬁcation system,
individuals with prehypertension could be easily identiﬁed
and counseled due to their increase risk of developing
hypertension and cardiovascular disease [6].
For donors, at least two blood pressure readings on two
separate occasions should be performed [2]. A donor who
has any elevated blood pressure reading is generally sent
for 24hr ambulatory blood pressure monitoring to rule out
white coat hypertension or to conﬁrm the abnormal ﬁnding.
A donor with a history of hypertension should undergo
furtherevaluationandquestioning.Ifthatdonorisontwoor
more medications, he is generally excluded [5]. If that donor
isononemedication,thenhecancontinueasadonoraslong
as he does not have evidence of target end organ damage.
Accordingtothe2007survey,41%ofcentersconsiderdonors
with well-controlled hypertension on one medication and
only 8% will consider donors on two medications [5]. For
the donors on one antihypertensive agent, documenting the
absenceofmicroabuminuria,leftventricularhypertrophy,or
other cardiac disease, dyslipidemia, obesity, or ophthalmo-
logic changes characteristic of hypertension is imperative.
In addition, this donor must demonstrate that his blood
pressure had been well controlled for at least six months
prior to evaluation and that he will have proper followup
postdonation for his blood pressure.
Racialvariationsinthedevelopmentofhypertensionand
chronic kidney disease in African Americans and Hispanics
have been described postdonation [7]. Because hypertension
may have poorer outcomes in African Americans and
Hispanics, ethnicity may play a role in excluding a larger
proportion of this population of hypertensive potential
donors or even these potential donors with an increased risk
of developing hypertension.
It is uncertain what to do with donors who are labeled as
prehypertensive. These donors are counseled in detail about
lifestyle modiﬁcation and their increased risk of developing
hypertension and cardiovascular disease. Of these who opt
to donate, postnephrectomy followup by their primary care
provider should be suggested.
Individuals with a family history of hypertension are
again counseled, as there is a genetic predisposition to
developing hypertension. Both paternal and maternal hyper-
tension are strongly associated with the development of
hypertension during adult life [8]. Careful counseling and
risk analysis should be done before these donors proceed.
2.1.3. Age. Fifty nine percent of centers in the U.S. have
no upper age limit. Approximately thirty percent of the
centers are using donors over the age of 65 [5]. Advanced age
(deﬁned as age above 65) may be associated with decreased
recipient graft and patient survival [9]. Biopsies from
donors over the median age of 57 years showed age-related
nephrosclerosis which may explain these inferior outcomes
[10]. Nevertheless, especially due to the shortage of live
donors, older donors should not be excluded. Conversations
should be undertaken with both recipient and donors in
regard to potential long-term disadvantages.
The majority of centers exclude donors younger than
18 years [5, 11]. Young donors should be evaluated on an
individual basis, and depending on their level of comprehen-
sion of kidney donation, their maturity level, their ability
to provide voluntary and valid consent, and their general
well being, they should be allowed to donate. Minors and
guardians should be informed of the gaps in our knowledge
regarding the long-term outcomes in minors with a solitary
kidney [12].
2.1.4. Pregnancy. Pregnant patients should not be evaluated.
It is not certain when a donor should be allowed to donate
post pregnancy [13]. In addition, given recent data on
pregnancy and donation, all female donors of childbearing
age who are contemplating pregnancy should be counseled
onthepotentialrisksofdonating.Womenpostdonationmay
have an increased risk for gestational diabetes, gestational
hypertension, preeclampsia, prematurity, and fetal loss [14].
Another study conﬁrmed the increased risk of preeclampsia
and hypertensive disorders of pregnancy [15].
Although there is no clear evidence as to the timing of
pregnancy postdonation, it is suggested that women should
delaypregnancyuntilatleasttwomonthstoayearpostdona-
tion to allow and assess for the degree of renal compensation
and to assess baseline blood pressures, GFR, and microalbu-
minuria [16, 17]. A high level of surveillance and monitoring
is suggested for all pregnant women postdonation [17].
2.2. Renal Issues
2.2.1. Glomerular Filtration Rate. While removal of a kidney
in a person with two normal functioning kidneys should
not result in progressive kidney failure, a large reduction
in nephron mass in a person who already has a decreased
baseline glomerular ﬁltration rate (GFR) can have adverse
consequences.
The most common approach to estimating GFR is with a
24-hoururineforcreatinineclearance.Approximatelyninety
percentofU.S.transplantcentersusethismethod[5].Inade-
quate collection, low protein diet, and other factors may lead4 Journal of Transplantation
to low creatinine clearances in those with actually normal
kidney function [13]. If the 24-hour creatinine clearance
is borderline, further evaluation with radionuclide methods
can be done [2]. These include iodine 124-iothalamate or
technetium 99m-diethylenetriamine. The general cutoﬀ for
most centers is GFR of 80mL/min/1.73m3 [5, 11].
2.2.2. Proteinuria. The majority of programs assess protein-
uria with a 24-hour urine collection [5, 11]. Other tests
that have been used but may not be able to replace the
24-hour protein collection include the spot urine protein
to creatinine ratio, spot urine albumin to creatinine ratio,
urine microalbumin, or 24-hour urine for albumin excretion
[5, 11] .W h i l em o s tp r o g r a m su s e>300mg/day in a 24-hour
urine collection as the cutoﬀ, a minority use >150mg/day as
ac u t o ﬀ [5].
2.2.3. Hematuria. All programs should perform a urinalysis
looking for microscopic hematuria. Obtaining any past
urinalysis as well as repeating another one would be helpful
to determine if the hematuria is transient or persistent.
Hematuria is considered signiﬁcant by one-third transplant
centers if there are more than 3 red blood cells/high powered
ﬁeld (RBC/HPF) [5].
If microscopic hematuria is found, an etiology should be
determined. Renal ultrasound which is the normal part of
the donor workup should be able to reveal most structural
causes of hematuria at the level of the kidney. Family
history of renal disease including polycystic kidney disease,
thin basement membrane disease, or Alport’s syndrome or
the presence of concomitant proteinuria can suggest an
underlying glomerular cause of hematuria in the donor. In
such cases, renal biopsy should likely be performed. Dysuria,
urinary frequency, and the presence of pyuria can suggest a
urinarytractinfection.Adonorwithafamilyhistoryofrenal
cell carcinoma or with a strong smoking history should be
evaluated for malignancy with a urologic evaluation, urine
cytology, and cystoscopy. In men, prostate issues should be
ruled out. In women, making sure the urine specimen was
not taken at the time of their menstruation is important.
African American patients should be screened for sickle
cell disease or trait. Asymptomatic nephrolithiasis should be
ruledoutaswell.Almosthalfoftransplantcenterswillaccept
donors with >10RBC/HPF if renal and urologic evaluations
are negative [5].
A kidney biopsy can identify unexpected pathology and
can assist in evaluating the donor. Correlations between a
time zero biopsy and donor characteristics have been made
leading to the following correlations: interstitial ﬁbrosis
and age, tubular atrophy and diastolic blood pressure and
proteinuria, arteriolar hyalinosis and serum creatinine and
estimated glomerular ﬁltration rate, mesangial increase, and
body mass index [18]. Long-term allograft outcomes in
donorswiththesehistologiccharacteristicsarestilluncertain
[19]. More recently, in a study of deceased donors, a donor
risk score using ten risk factors was calculated and used to
prognosticate the chronic allograft damage index (CADI)
using a histologic grading system [20]. This study showed
a correlation between donor risk scores, greater degree of
histologiclesions,andworsegraftoutcomes.Whetherkidney
biopsy should be done in all potential living donors requires
further studies, taking into account risk of the biopsy itself,
and sampling error. Deﬁnite indications may be persistent
unexplained microscopic hematuria or proteinuria, or any
other uncertainty of a possibility of underlying glomerular
disease in the potential donor. If the histopathology is
consistentwithglomerulardiseasethedonorshouldberuled
out.
2.2.4. Nephrolithiasis. Nephrolithiasis with development of
obstruction of a single kidney can have catastrophic conse-
quences yet a history of nephrolithiasis need not preclude
donation as long as certain conditions are met. The number
of stones the potential donor has formed in the past needs
to be determined. For example, if a donor has a history of
nephrolithiasis but the disease has been quiescent for years
and there are no abnormalities in metabolic or radiologic
testing, then donating can be acceptable [2]. This donor,
however, should be informed that his lifetime risk for
developing another stone can be 14% at 1 year, 35% at 5
years, and 52% at 10 years [21] .I f ,h o w e v e r ,ad o n o rh a s
had recurrent episodes of nephrolithiasis, he or she should
be discouraged from donating.
Theotherendofthespectrumincludesthosewhodonot
give a history of nephrolithiasis but are found to be asymp-
tomatic stone formers. Stones may be noted incidentally
while doing screening renal ultrasounds as part of the donor
evaluation. In addition, some donors may have a strong
family history of nephrolithiasis. These donors can likely be
accepted but must be cautioned about their increased risk
of developing another kidney stone in their solitary kidney
during their lifetime.
2.3. Lifestyle Issues
2.3.1. Overweight and Obesity. Potential donors who are
either overweight or obese pose a number of issues. Some
of these relate to the perioperative period where the risk of
complications during this time is increased. However, there
are special long-term considerations as well and donation of
a kidney in someone who is obese may enhance their risk of
eventually developing kidney disease. It should also be noted
that the increasing prevalence of obesity may prove to be a
substantial limiting factor to rates of kidney donation.
All donors should have their height and weight checked
during their initial visit. Body mass index (BMI) is then
calculated which is deﬁned as weight in kilograms divided by
height in meters squared. Those with BMI between 25kg/m2
and 29.9kg/m2 are considered overweight and those with
BMI greater than 30kg/m2 are considered obese. Obesity is
further subclassiﬁed into class I (BMI of 30.0 to 34.9kg/m2),
class II (BMI 35.0–39.9kg/m2), and class III (BMI greater
than 40kg/m2). Higher baseline BMI has been shown to be
an independent risk factor for end-stage renal disease [22].
The majority of transplant centers exclude potential
donors with a BMI over 35kg/m2 [5]. Those with BMI overJournal of Transplantation 5
a3 0k g / m 2 but less than 35kg/m2 should be counseled on
lifestyle modiﬁcations especially weight loss. In addition,
they should be made aware of the long-term associations
of obesity with the development of hypertension, diabetes
mellitus, metabolic syndrome, and kidney disease, including
end-stage renal disease.
2.3.2. Smoking. Smoking is an area of concern for a number
of reasons but is currently not a contraindication to donate.
While the postoperative risks of poor wound healing and
pulmonary infections in smokers are known [16], the long-
term eﬀects of smoking on the kidneys are uncertain. In
a recent study, smoking has been shown to be associated
with an increased risk of developing proteinuria possibly
through glomerular hyperﬁltration [23]. On the contrary,
in a study of living donors, smoking status was not a risk
factorforlong-termdeclineinglomerularﬁltrationrate[24].
With this in mind, due to the negative postoperative risks
and extrarenal long-term eﬀects of smoking, donors should
be counseled on smoking cessation and advised about the
negative consequences of smoking.
2.3.3. High-Risk Behaviors. Donors should have behavioral
screening in addition to infectious disease testing. Sexual
history and drug history should be examined in detail. They
should be interviewed in a conﬁdential manner and should
be asked direct questions. Issues of concern are promiscuity;
men who have had sex with other men in the previous ﬁve
years; anyone exposed to or who has had sexual relations
with someone at risk for, or with HIV, HCV, or HBV in the
preceding year; donors with a history of hemophilia; donors
with history of blood transfusions or any human-derived
clotting factor concentrates; intravenous, intramuscular, or
subcutaneous drug use in the preceding ﬁve years; men or
women who have had sex in exchange for money or drugs
in the previous ﬁve years; incarceration [25]. A substantial
disadvantage of these donors is the potential to transmit
infectious diseases, namely, HBV, HCV, and HIV.
Depending on the situation, donors can be excluded if
their risk to the recipient is very high. If they are currently
engaging in any high-risk behavior, they should be advised
of their obligation to avoid the high-risk behavior. If they
cannot avoid it, they should be given the choice to opt out
of donating with a medical excuse. Due to the high risk,
the recipient advocate and recipient should be made aware
of the potential increased risk to the recipient for infectious
diseases [26]. Informed consent from the recipient should be
obtained and documented in regard to this [26].
It is controversial at this point whether to repeat serology
orperformNATforHBV,HCV,andHIVinhigh-riskdonors
two to four weeks prior to transplant. The purpose of NAT
would be to detect the disease at the time period between
infection and detectability of antibodies. The downside of
NAT is that it costly, takes longer to perform and may result
in false positives [27].
2.4. Psychosocial Issues. A thorough psychosocial evaluation
adds to the comprehensive evaluation of the donor. Ideally,
this evaluation should be done by a social worker and/or
psychiatrist who has experience in evaluating donors. The
goal of this evaluation is to evaluate the psychological,
social, and emotional stability of the potential donor [12].
In addition, the donor’s ability to give informed consent,
their underlying motivation to donate, their relationship to
the recipient, and any economic or social hardships that the
donor may encounter during or after the process are sought
after [28].
An in-depth evaluation of the donor’s current mental
condition should be done. Any donor with a history of
any psychiatric disorder, including major depressive disor-
der, bipolar disorder, generalized anxiety disorder, mood
disorder, or any personality disorder should be assessed
for any signs or symptoms of instability. A donor should
be asked about any childhood or adolescent problems that
suggest mental health issues, suicidality, homocidality, inpa-
tient psychiatric hospitalizations, or outpatient psychiatric
evaluations. A thorough assessment of any medications
that they were taking or currently taking should be done,
keeping in mind any medications that could potentially be
nephrotoxic. For example, if a donor has been stable on
lithium carbonate and cannot be taken oﬀ of it due to fear of
relapse,thatdonorshouldlikelynotdonate[13].Inaddition,
the evaluator must try to foresee any potential problems
that can arise during the postdonation period, and any risk
of recurrence. In fragile donors, evaluation and counseling
should extend to the donor during the postdonation period
to assure psychological well being. Testing focusing on the
donor’s level of cooperation, eye contact, speech, language,
mood, aﬀect, thought process, thought content, memory,
orientation, insight, and judgment should all be noted.
Donors should not have any evidence of active drug or
alcohol abuse. Generally, a period of at least six months of
abstinence is acceptable for a donor [13]. Again, the high-
risk donor can be identiﬁed at this time as well with a
detailed and thorough sexual history and counseled in an
appropriate manner. Smoking cessation can be discussed at
this evaluation as well.
The relationship between the donor and the recipient
should be established, as well as what is motivating the
donor to donate. Any suggestion of coercion or guilt should
be further evaluated, making sure that the donor is not
threatened in any way and that there is no gain—either
ﬁnancial or personal. In other words, the donor should
be making decisions out of his free will. Other donor and
family relationships should be addressed, looking for any
signs of marital problems, or any hardships that the donor
or evaluator can foresee as a result of donation. Evaluation
of the donor’s social support system must be made [28].
Any potential economic loss should be evaluated. If time
oﬀ from work during the postdonation period could cause
the donor to lose his job or lose major income, the donor
should reconsider. Any out-of-pocket expenses for travel,
lodging, or miscellaneous expenses related to transplant or
inability to obtain sick leave should be discussed with the
donor [12, 28]. Education level and socioeconomic status
shouldbeevaluated,makingsurethatthesedonotplayarole
in the donation process. These can sometimes be a barrier6 Journal of Transplantation
to informed consent or to the donor’s understanding of the
entire process [29]. The donor’s religious beliefs should be
evaluated as well, making sure that the donor is not being
motivated by certain beliefs [29].
2.4.1. Obtaining Informed Consent. Donors must demon-
strate competence and understanding regarding the dona-
tion process and recipient health. He must also receive all
the accurate information to make a decision. The donor
should demonstrate understanding of the recipient’s illness
and should understand the other options for the recipient,
including deceased donor transplantation or dialysis. He
should be able to describe to the best of his knowledge
why the recipient needs a transplant. The donor should
be able to demonstrate understanding of the nephrectomy
including the risks and beneﬁts to the recipient, the risks and
beneﬁts to the donor, the postoperative course, the short-
and long term-outcomes associated with nephrectomy, the
possibility of rejection, and the possibility that the donor
may need the sacriﬁced organ in the future. All preoperative
workup, expenses, and postoperative surgical complications
andexpectedoutcomesshouldbefullydisclosedtothedonor
[12].
The donor should demonstrate that he is free of coercion
or any outside inﬂuence and that his decision to donate is
voluntary [12, 13]. The donor must have the capacity to
give informed consent. He must have passed the social and
psychosocial evaluation with no major issues. The donor
must also be made aware of his right to reconsider donation
atanypointduringtheevaluation,ofhisrighttooptoutwith
a medical excuse, and of the conﬁdentiality of the donation
process [29].
3. Donor Assessment to Protectthe Health and
Safety of the Recipient
3.1. Infection. Kidney donation entails the risk of trans-
mission of an infectious disease to a recipient who will
be subjected to signiﬁcant immunosuppression. Hence, the
presence of any such infection must be tested for.
All donors must be screened for active and past com-
municable infections. This testing should include human
immunodeﬁciency virus 1 and 2 (HIV-1 and HIV-2), human
T lymphotropic virus type-1 (HTLV-I) and type-2 (HTLV-
II), hepatitis A, hepatitis B, hepatitis C, and syphilis. In
addition, donors are further tested for cytomegalovirus
(CMV), epstein-barr virus (EBV), toxoplasmosis, herpes
simplex virus (HSV), and varicella zoster virus (VZV).
Screening for HIV should include serum enzyme-linked-
immunosorbent assay (ELISA) for HIV-1 and HIV-2 using
U.S. Food and Drug Administration licensed screening tests.
Combination HIV-1/HIV-2 tests are available. Screening for
Hepatitis B should include qualitative detection of hepatitis
B surface antigen (HBsAg) and antibodies to hepatitis B core
antigen(Anti-HBc,IgG,andIgM)andtoHBsAg(Anti-HBs).
Screening for hepatitis C can be with antibody testing to
hepatitis C virus (Anti-HCV). Whether nucleic acid testing
(NAT) should be done in addition to or in place of the
above is unknown and case-dependent. Per Centers for
Disease Control and Prevention (CDC) recommendations,
all recipients should be counseled that negative tests for
HBV, HCV, and HIV do not confer absence of disease, as
the donor could have donated after infection but before
serocoversion[25].SyphiliscanbescreenedforwithVenereal
Disease Research Laboratory (VDRL) or Rapid Plasma
Reagin (RPR). HTLV I/II screening is done with ELISA.
Having any of the above active infections would be a
contraindication to donate. Having positive testing for HIV,
HCV, HBsAg, or anti-HBc, IgM positivity would be a
contraindication to donate. Hepatitis B Core Antibody IgG
positivity in an HbsAg-negative donor carries a small risk
of transmission and such donors should be excluded [30].
Being Anti-Hbs positive is not a contraindication as this
could signify vaccination or long-term immunity. Here,
history can elicit which is the etiology. Having past infection
with toxoplasmosis, CMV, VZV, HSV, or EBV is not a
contraindication to donate. Syphilis does not contraindicate
a person from donating as the risk of transmission is very
low but the donor should be treated prior to donation and
the recipient should be treated with penicillin posttransplant
[30]. Being HTLV-I-positive should ideally be a contraindi-
cationgiventherecouldbeincreasedriskformyelopathyand
adult T cell leukemia in the immunosuppressed recipient.
Given minimal chance of HTLV-I/II disease in the recipient
approximately 12 months posttransplant, careful considera-
tion can be given to these donors [31]. Long-term outcomes,
however, are not available and one should proceed with
caution, after obtaining appropriate informed consent.
Screening for Strongyloides, Trypanosoma Cruzi,W e s t
Nile Virus, Tuberculosis with puriﬁed protein derivative
testing or the interferon gamma release assay should be done
ondonorsfromendemicareasifthesediseasesaresuspected.
3.2. Malignancy. Kidney donation entails a potential risk
of transmission of malignancy to the immunosuppressed
recipient. With careful evaluation of donors, unintentional
transmission of cancer should be avoidable. The evaluation
of potential malignancy in the donor should begin with
age appropriate health maintenance screening. Recommen-
dations per the U.S. Preventative Task Force are as follows:
all women who are sexually active and have a cervix or
those above 18 years of age should have pap smears. Biennial
screening mammography for women beginning at age 50
should be performed. Screening for colorectal cancer using
fecal occult blood testing, sigmoidoscopy, or colonoscopy, in
adults, should generally be done beginning at age 50 years
[32]. In male donors age 50 or above, whether symptomatic
or not, prostate screening testing should be performed with
digitalrectalexaminationandprostatespeciﬁcantigen(PSA)
[2]. If there is a family history of malignancy, screening
should be done at an earlier age after discussion with the
donor [2].
According to the Disease Transmission Advisory Com-
mittee (DTAC) Malignancy Subcommittee, donors can be
categorized into risk categories including no signiﬁcant risk,
minimal, low, intermediate, high, or unknown risk [33].Journal of Transplantation 7
Each of these risk categories divides patients according to
speciﬁc tumor type. Absolute contraindications and high-
risk donors include those with a history of lung, breast,
renal, or other urologic cancers, melanoma, neuroendocrine
tumors, or small cell carcinoma any site of origin, mono-
clonal gammopathy, choriocarcinoma, testicular cancer, gas-
trointestinal, or hematologic malignancy such as leukemia
or lymphoma [2, 33]. Donors of the high-risk category
carry a greater than 10% transmission rate. Minimal risk
category patients include those with basal cell carcinoma of
the skin, squamous cell carcinoma of the skin, in situ cervical
cancer, in situ vocal cord carcinoma, and certain thyroid
cancers [33]. These donors carry a <0.1% transmission risk.
Transmission risks are meant to provide a basis from which
t os u g g e s tl e v e l so fc o n c e r n ,a st r u et r a n s m i s s i o nf r e q u e n c y
estimates have not yet been established [33, 34].
It is advised that every precautionary measure be taken.
During organ retrieval, if a suspicious mass or nodule is
found, biopsy should be performed and prompt frozen
section examination should be done [35].
4. Conclusions
The ﬁnal decision for transplantation should respect the
donor’s autonomy and decision to donate, the recipient’s
right to accept, and the respective transplant teams’ medical
decision making to proceed for living donor transplantation
[12]. All parties involved must be free of coercion. The risk
and beneﬁt analysis for the donor should be to provide
more good than harm. If the opposite is the case, then
transplantationshouldnotproceed.Thetaskmaybediﬃcult
but if done carefully will result in good outcomes.
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